What is an eQMS for medical devices — and why most of them don't actually pass QSIT

Every medical device company has a quality management system. Most of them also have an eQMS. Those are not the same thing, and the gap between them is where FDA 483s come from.

The eQMS is the software. Document control, CAPA module, complaint tracking, audit management, training records. It's the thing that shows up on product demos with progress bars and approval workflows. The QMS is what actually happens — whether procedures get followed, whether CAPAs produce effective action, whether the records reflect the work. The eQMS is supposed to be the enforcement mechanism for the QMS. In practice, for most manufacturers I've seen, it's a parallel documentation system that the real work happens around.

What an eQMS is supposed to do

FDA 21 CFR Part 820 and ISO 13485:2016 both require a documented quality management system covering a specific set of activities. The eQMS is how you operationalise those requirements at scale. Five domains carry most of the weight.

Document control. Every procedure, specification, work instruction, drawing, and protocol needs version control, review, approval, and restricted distribution. Paper works for small companies. Past about 20 people, paper breaks down. The eQMS enforces approval before effectivity, keeps history, and gates access by role.

CAPA. Corrective and preventive action is where most 483s concentrate. FDA 483 analysis published in the last five years consistently puts CAPA-related observations in the top three — usually top two. The weakness isn't that companies don't have CAPA procedures. It's that the CAPAs that get opened don't produce effective corrective action, or the effectiveness isn't verified, or the verification isn't documented. The eQMS can enforce the workflow but can't enforce the thinking.

NCRs. Nonconformance reports capture deviations during manufacturing or testing. The ones that matter connect to design records, risk analysis, and associated changes. Where they don't connect, you get a disposition pattern that FDA flags: NCRs opened, NCRs closed, no traceability to whether the underlying design issue was actually addressed.

Complaints and adverse event reporting. Field complaints feed back into CAPA, may require MDR reporting under 21 CFR Part 803, may trigger recalls. The reporting timelines are tight — 30 days for most MDRs, 5 days for device-related deaths. An eQMS that can't reliably trigger timely reports puts the company in immediate regulatory exposure.

Audits and inspections. Internal audits, supplier audits, FDA inspections, notified body audits. The eQMS holds the audit records, findings, corrective actions, and closure evidence. Audit readiness is the ability to produce every record needed on demand — which assumes the records are organised the way auditors actually look for them, not the way the quality team filed them.

Why most eQMS implementations don't pass QSIT cleanly

FDA's Quality System Inspection Technique audit is process-based. The inspector pulls a thread — usually a complaint, a design change, or a nonconformance — and follows it across processes. Does the complaint record reference the design decisions at issue? Did the CAPA that came out of the complaint trigger a risk file update? Was the risk update verified? Did the corresponding design change go through design controls properly?

The typical eQMS is organised by module. Complaint handling is one module. CAPA is another. Design controls live in PLM, which is a different system. Risk management is either in the eQMS or in a spreadsheet depending on the company. Each module is internally consistent. The connections between them are maintained manually, and they drift.

When the inspector follows a thread across those modules, they find the drift. Records disagree about when the CAPA was opened. Risk file doesn't reflect the design change the CAPA triggered. Effectiveness verification references a test that was never run. Each disagreement is a finding. Each finding is a 483 observation. None of them are deliberate — the quality team was honestly trying to run the system. The architecture made the drift inevitable.

Why engineering teams hate the eQMS

Ask any engineering team whose company implemented an enterprise eQMS. You'll hear the same thing. The eQMS slowed everything down. Design reviews take longer. Change orders bog down. Approval workflows that used to happen in a meeting now take two weeks. Engineering time gets spent on documentation tasks that feel redundant with the work they already did.

The feeling is correct. The eQMS was designed for quality professionals, not engineers. Every action maps to a quality-system artefact the engineer didn't generate and doesn't control. The engineer made the design decision in CAD, in requirements management, in source control. Now they're translating that decision into forms the eQMS expects, in a system they don't live in, at a level of formality that doesn't match how they reason.

That translation is where errors enter, and where the linkages between engineering work and quality records weaken. Not because engineers are careless. Because the translation is a separate job from the work they were hired to do.

What a unified PLM and eQMS changes

PLM holds design intent — BOMs, CAD, requirements, V&V results, design controls. eQMS holds quality records. Historically, separate systems, separate teams, separate data models.

When they share a data model, the relationship between a design decision and its quality implications stops being a cross-reference problem. It becomes a property of the record. A design change knows which risk controls it may affect, which NCRs reference it, which CAPAs it closes or opens. That cascade is deterministic. It doesn't depend on someone remembering to update the other system.

This is the architectural premise behind MANKAIND. When engineers make design decisions inside the platform, those decisions are quality-system aware from the moment they exist. The quality record follows automatically. CAPAs link to the design artefacts they came from. NCRs reference the specifications they violated. Audit readiness becomes a byproduct of engineering discipline rather than a separate compliance effort layered on top.

What regulators actually require

FDA 21 CFR Part 820 — updated 2024 to align more closely with ISO 13485:2016 — specifies quality system requirements for US-market medical devices. ISO 13485:2016 is the international equivalent, required for EU CE marking and accepted by Canada, Australia, Japan, and Brazil. MDSAP audits run against ISO 13485 plus regulator-specific layers.

Both frameworks expect the same thing at the structural level. Quality records must be complete. They must be traceable. They must be available on demand. Manufacturers who meet that expectation confidently have platforms that connect engineering to quality natively. Manufacturers who scramble before every audit have platforms that treat them as separate problems.

The actual question worth asking

Feature checklists are useless. Every enterprise eQMS has every module. That's not what distinguishes them.

The question is whether the engineering decisions that drive quality outcomes are captured as part of the engineering workflow, or whether your team maintains the connection manually between two systems.

Manual maintenance compounds. Every design iteration is a new reconciliation task. Every audit is an excavation exercise. Every inspector thread that crosses modules is a potential finding. That's the architecture tax. It doesn't show up on a feature comparison, but it shows up in 483 frequency, in submission delays, and in the engineering time you lose to documentation work.

Frequently asked questions about eQMS for medical devices

What is an eQMS for medical devices?

An electronic Quality Management System (eQMS) is the software infrastructure medical device companies use to manage document control, CAPAs, nonconformance reports, complaints, audits, supplier qualification, and training records required by FDA 21 CFR Part 820 and ISO 13485:2016.

Is an eQMS required for FDA compliance?

FDA 21 CFR Part 820 requires a documented quality management system for medical device manufacturers. The regulation does not mandate electronic format, but in practice a well-designed eQMS is how manufacturers demonstrate document control, CAPA rigor, and audit readiness at scale.

What is the difference between a QMS and an eQMS?

A QMS is the quality management system itself — the processes, procedures, and records. An eQMS is the electronic software platform used to operate that system. The eQMS enforces version control, approval workflows, and traceability in ways paper systems cannot.

Can an eQMS and PLM be on the same platform?

Yes. MANKAIND unifies PLM and eQMS so that design decisions made in the engineering workflow automatically update quality records. This eliminates the manual reconciliation between separate systems that causes most CAPA and traceability failures in traditional implementations.

Which ISO standard applies to an eQMS for medical devices?

ISO 13485:2016 specifies requirements for medical device quality management systems. Certification is required for EU market access under the EU MDR and IVDR and is accepted by regulators in Canada, Australia, Japan, and Brazil.